Allena Pharmaceuticals (Allena Pharmaceuticals) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Allena Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Allena Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Jun. 2022 was 0.00.

Allena Pharmaceuticals's long-term debt to total assets ratio declined from Jun. 2021 (0.34) to Jun. 2022 (0.00). It may suggest that Allena Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Allena Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Allena Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allena Pharmaceuticals LT-Debt-to-Total-Asset Chart

Allena Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.15

0.18

0.26

0.01

Allena Pharmaceuticals Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.34	0.23	0.01	-	-

Allena Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Allena Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )	/	Total Assets (A: Dec. 2021 )
	=	0.21	/	34.757
	=

Allena Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2022 is calculated as

LT Debt to Total Assets (Q: Jun. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2022 )	/	Total Assets (Q: Jun. 2022 )
	=	0	/	17.811
	=

Allena Pharmaceuticals (OTCPK:ALNAQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Allena Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Allena Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allena Pharmaceuticals Inc (OTCPK:ALNAQ) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Newton Executive Park, Suite 202, Newton, MA, USA, 02462

Website

https://www.allenapharma.com

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

Executives

Louis Md Brenner	officer: See Remarks	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140
Mark J. Fitzpatrick	director	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Richard D Katz	officer: Chief Financial Officer	4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703
Edward Wholihan	officer: Chief Financial Officer	C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Bessemer Venture Partners Vii L.p.	10 percent owner	C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538
Hbm Biocapital Ii Lp	10 percent owner	11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH
James N Topper	director, 10 percent owner	550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301
Fhm Vi, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert I Tepper	director, 10 percent owner	201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Robert Alexander	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Alexey L Margolin	director, officer: Chief Executive Officer	C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139